BiotechTube

Camrelizumab plus TP + TP

Phase 3Recruiting
0 views this week 0 watching⚡ Active
Interest: 47/100
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Oral Squamous Cell Carcinoma

Conditions

Oral Squamous Cell Carcinoma

Trial Timeline

Nov 21, 2023 → Oct 1, 2026

NCT ID
NCT05798793

About Camrelizumab plus TP + TP

Camrelizumab plus TP + TP is a phase 3 stage product being developed by Jiangsu Hengrui Medicine for Oral Squamous Cell Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05798793. Target conditions include Oral Squamous Cell Carcinoma.

What happened to similar drugs?

5 of 20 similar drugs in Oral Squamous Cell Carcinoma were approved

Approved (5) Terminated (2) Active (14)
✅AmifostineSun PharmaceuticalApproved
✅tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
✅Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
✅Tranexamic Acid plus standard of carePfizerApproved
✅BivigamADMA BiologicsApproved
❌AL001 + Placebo + Open label - AL001AlectorPhase 3
🔄Micafungin + FluconazoleAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05798793Phase 3Recruiting

Competing Products

20 competing products in Oral Squamous Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
AL001 + Placebo + Open label - AL001AlectorPhase 3
22
AL001AlectorPhase 2
25
AG013OragenicsPhase 2
17
LP-10 (Liposomal Tacrolimus)Lipella PharmaceuticalsPhase 2
29
Micafungin + FluconazoleAstellas PharmaPhase 3
40
micafungin + caspofunginAstellas PharmaPhase 3
40
Erlotinib + PlaceboAstellas PharmaPhase 3
40
AmifostineSun PharmaceuticalApproved
35
exenatide + Other antidiabetic therapiesEli LillyPre-clinical
26
Teriparatide 20 mcgEli LillyPhase 3
40
LY3884963 + Methylprednisolone + Optional Sirolimus + Optional PrednisoneEli LillyPhase 1/2
36
Baricitinib 4 milligram Oral TabletEli LillyPhase 2
39
tramadol hydrochloride + acetaminophenJohnson & JohnsonApproved
43
Essential oils + 0.2% chlorhexidine + Sterile waterJohnson & JohnsonApproved
43
galantamine hydrobromideJohnson & JohnsonPhase 2
35
HR17031 injection + insulin glargineJiangsu Hengrui MedicinePhase 3
40
Camrelizumab + Camrelizumanb plus TPFJiangsu Hengrui MedicinePhase 2
35
AZD1981 + Neovletta 21/28 + Placebo AZD1981AstraZenecaPhase 1
29
DurvalumabAstraZenecaPhase 1/2
36
fostamatinib + Microgynon® 30 (Oral contraceptive) + PlaceboAstraZenecaPhase 1
29